SCHEMBL20583575

SCHEMBL20583575

CC(C)OC(=O)[C@H](C)CC(=O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.50
▸ PDCD1 Q15116 1/20 0.49
▸ CD274 Q9NZQ7 1/20 0.49
▸ GAA P10253 2/20 0.47
▸ ABCC4 O15439 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ PTGS1 P23219 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ MAPT P10636 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ FAAH O00519 1/20 0.43
▸ MMP12 P39900 2/20 0.43
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20583574 1.00 TSHR (0.50) TSHRPDCD1CD274GAAABCC4
SCHEMBL20583484 0.87 ALDH1A1 (0.50) TSHRGAAABCC4LMNAPTGS1
SCHEMBL20583485 0.87 ALDH1A1 (0.50) TSHRGAAABCC4LMNAPTGS1
SCHEMBL21249535 0.86 GAA (0.47) TSHRGAAABCC4LMNAPTGS1
SCHEMBL21572799 0.86 GAA (0.47) TSHRGAAABCC4LMNAPTGS1
SCHEMBL21572796 0.84 ALDH1A1 (0.47) TSHRGAAABCC4LMNAPTGS1
SCHEMBL29629669 0.84 ALDH1A1 (0.47) TSHRGAAABCC4LMNAPTGS1
SCHEMBL21572785 0.83 GAA (0.45) TSHRGAAABCC4LMNAPTGS1
SCHEMBL18970284 0.83 ABCC4 (0.55) TSHRGAAABCC4LMNAPTGS1
SCHEMBL18970304 0.83 ABCC4 (0.55) TSHRGAAABCC4LMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370739-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-06-28 — — US disclosed
US-11370739-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-06-28 — — US disclosed
EP-3424899-B1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-05-11 — — EP disclosed
EP-3424899-B1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-05-11 — — EP disclosed
US-20200079721-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) 2020-03-12 — — US disclosed
US-10479753-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD (CN) 2019-11-19 — — US disclosed
US-10479753-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD (CN) 2019-11-19 — — US disclosed
EP-3424899-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2019-01-09 — — EP disclosed
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079721-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF DPP4, ACE, DPP8 TSHR 3965/4885PDCD1 4142/4885CD274 4608/4885
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF ACE, DPP4, SI TSHR 3906/4885PDCD1 3644/4885CD274 4444/4885
US-11370739-B2 Sacubitril intermediate and preparation method thereof DPP4, ACE, DPP8 TSHR 3965/4885PDCD1 4142/4885CD274 4608/4885
US-10479753-B2 Sacubitril intermediate and preparation method thereof ACE, DPP4, SI TSHR 3906/4885PDCD1 3644/4885CD274 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback